Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Debt (2016 - 2025)

China Pharma Holdings filings provide 16 years of Total Debt readings, the most recent being $2.0 million for Q4 2025.

  • On a quarterly basis, Total Debt fell 22.04% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a 22.04% decrease, with the full-year FY2025 number at $2.0 million, down 22.04% from a year prior.
  • Total Debt hit $2.0 million in Q4 2025 for China Pharma Holdings, up from $2.0 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $5.1 million in Q3 2021 to a low of $2.0 million in Q3 2025.
  • Median Total Debt over the past 5 years was $2.6 million (2024), compared with a mean of $3.0 million.
  • Biggest five-year swings in Total Debt: skyrocketed 91.76% in 2021 and later tumbled 47.58% in 2023.
  • China Pharma Holdings' Total Debt stood at $4.3 million in 2021, then plummeted by 43.61% to $2.4 million in 2022, then grew by 0.07% to $2.4 million in 2023, then rose by 3.83% to $2.5 million in 2024, then fell by 22.04% to $2.0 million in 2025.
  • The last three reported values for Total Debt were $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.